ArticleDrugs in context2025
Management of refractory generalized myasthenia gravis with eculizumab during pregnancy and puerperium: a case report.
Article in Drugs in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) mostly affects women of childbearing age. Since the disease course may be affected during pregnancy and postpartum, monitoring and appropriate treatment of MG in pregnant women are crucial. Current treatment options for pregnant women with refractory MG are limited by possible teratogenicity and inadequate lactation data. This case report describes a successful pregnancy in a patient who received eculizumab for refractory generalized MG that was difficult to manage during the pre-pregnancy period. We also report the experience of preterm labour and neonatal MG and the 1-year follow-up of the neonate. Considering the risk-benefit balance, eculizumab can be recommended during pregnancy and postpartum, especially in women with refractory generalized MG.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.